The medical team members may be frustrated or believe they've exhausted the workup studies, and they may prefer not to order any more. They may not be too keen on continuing the same antibiotics. The ICU team hungers for something new and preferably simple. As I review the differential diagnosis, with dis claimers as to why any given di agnosis does or does not ade quately explain the fever, I get a feeling of déjà vu. The team has heard these ruminations from me and my colleagues many times, and I suspect that by now the discussion is minimally compel ling or interesting academically. This is not the multidimen sional "great case" that FUOs were once advertised to be -the cases presented on chiefofser vice rounds in which an expert diagnostician pontificates about the differential diagnosis of rare or subtle disease complexes and their presentations. Given the na ture of the illness in many of these patients, the conferences are more likely to be family con ferences that include plans for palliative care. If the old FUOs were sometimes exhilarating, the FTMOs can be debilitating. Al though some patients will recover and be discharged to lead full and active lives, many will either die or be sent to a longterm care facility.
We debate whether using anti biotics in apparently futile situa tions is ethical. After all, we may "create" some extremely resistant bacteria in one patient that could be transmitted to others. Alter natively, antibiotics may be life saving. There are few directives, ethical guidelines, or clinical path ways to follow in these cases. As I mull over the options, I am dis heartened by the knowledge that whether I use or withdraw anti biotics (asking the team to ob serve the patient closely) or re quest more testing, I may simply be deferring the tough decisions for another day. Medicines are designated as es sential on the basis of their effi cacy and safety, availability, ease of use in various settings, compar ative costeffectiveness, and pub lic health need. In many coun tries, the list forms the basis of national drug policies. Govern ments and health ministries often refer to it when making decisions regarding resource allocation and health care spending. The list does not include all efficacious medicines, the latest medicines, or even all medicines needed in a country. Rather, it helps to define the minimum medicine needs for a basic health system.
Although some protein con centrates (factors VIII and IX and immunoglobulins) are listed, no labile blood components are on the Model List. The reason for their absence is unclear. Certain ly, the lengthy, exhaustive process for applying for a listing can be discouraging: each component re quires a separate detailed, complex application. Most medicines are proposed by manufacturers with a commercial interest in having their products listed. There has been no similar advocacy for blood components that are collected and prepared by notforprofit organi zations, until now.
There are compelling reasons to add whole blood and redcell concentrates to the list. Blood transfusion originated as a medi cal practice requiring either sur gical intervention to join donor to recipient or a licensed practitioner to draw and immediately infuse blood. The development of anti coagulant preservative solutions early in the 20th century and, later, sterile bottles and plastic blood bags permitted blood to be stored, which effectively distin guished the product that must meet defined standards from the medical practice of transfusion -a distinction that's critical to understanding why blood compo nents are treated and regulated as drugs.
Is blood an essential medicine? Despite the dearth of random ized clinical trials, blood is clear ly essential. Redcell transfusion is one of the few treatments that adequately restore tissue oxygena tion when oxygen demand exceeds supply. Despite wellpublicized in fectious and immunologic adverse events, redcell transfusion has a therapeutic index exceeding that of many common medications. 2 In developed countries, most sur gical procedures would not be undertaken without the availabil ity of blood. The majority of units are transfused to support surgery, chemotherapy, stemcell transplan tation, and management of in herited disorders such as thalas semias and sickling syndromes. Blood is used differently in the developing world, where for logis tic reasons, whole blood may still be the preparation of choice, 3 but a reliable supply of safe blood is crucial. Numerous deaths result ing from trauma, hemorrhage dur ing childbirth, and the hemolytic anemia of childhood malaria are preventable. Too often, a reliable source of safe blood is lacking because of inadequate resources, infrastructure, oversight, or na tional will.
The question of whether blood is a medicine seems more con tentious. Blood is certainly a sub stance used to treat, mitigate, or prevent disease. Whereas whole blood and red cells differ from smallmolecule pharmaceuticals in their unittounit heterogeneity (batch variability), blood compo nents are biologics that share many attributes with those medi cines. Technical and regulatory developments during the past half century have led to the manufac ture of blood components for purity, potency, and safety. Blood donors are qualified as suppliers of raw material by rigorous selec tion and testing standards. Units undergo inprocess quarantine; quality control to ensure that re agents, equipment, and methods perform as expected; temperature monitoring; batch release after suitability determination; and la beling for identity, content, expi ration date, and intended use. Once issued, blood components are subject to standards for traceability, and many countries have developed hemo vigilance systems that parallel pharmaco vigilance systems.
Like other medicines, blood has its defined medical indications and recognized adverse effects and may be administered only by doctor's order or prescription. International product standards for manufacture of blood compo nents underscore the need for supplier qualification, trained per sonnel, qualitysystem essentials, and validation of equipment, facili ties, and processes. 4, 5 Common to all bloodcomponent regula tions are requirements to assure that blood components meet prod uct standards through controls on manufacturing, and the WHO recently published guidance for Good Manufacturing Practices for blood establishments.
In many jurisdictions, blood is already regulated as a drug. In the United States, blood and other biologics became subject to regu lation as medicines under the Food, Drug, and Cosmetic Act in 1938 and subject to licensing in 1944. In Canada and Germany, blood and blood components are regulated as biologic medicines; in Japan, they are regulated under the Pharmaceutical Affairs Law; and in Australia, bloodcomponent manufacturers are licensed to en sure that products meet Council of Europe standards. Blood is listed in several national formu laries, including the U.S. Pharma copeia.
Adding whole blood and red cells to the Model List of Essen tial Medicines would boost aware ness of the global need for blood and of blood's role in protecting the public health. Listing would underscore governments' respon sibility for sustainable funding of a safe, adequate, accessible blood supply. It would call attention to the importance of appropriate regulatory oversight of blood col lection, processing, testing, and distribution to ensure safety and quality, as well as the need for adherence to guidelines for clini cal use. Finally, listing would em phasize the need to ensure that blood is costeffective and afford able. The last three benefits are particularly relevant for low and middleincome countries.
Concern has been expressed that including blood on the Model List might erode principles relat ed to volunteerism and altruism and increase the cost of blood, but I don't believe that would happen. Designating blood as a medicine should neither introduce blood sales and donor payment in countries where they don't exist nor accelerate commercialization of blood in countries where they do. On the contrary, listing on a WHOsponsored document should emphasize the desirability of vol untary, nonremunerated blood donation and the notforprofit status of bloodcollecting organi zations -policies that the WHO endorses and that were stressed again in a 2011 World Health As sembly resolution. These principles can also be established within a country through legislation or policy and can be achieved with in a biologics manufacturing en vironment. Additional concerns are that treating blood as a medication might increase costs and interfere with the function of blood sys tems that have grown up outside the oversight of health ministries and other regulatory agen cies. The immediate direct costs of intro ducing regulated manufacturing systems are high, but indirect sav ings from improved patient out comes and donor safety, though harder to calculate, are substan tial. Furthermore, the manufac ture of blood components that meet set quality standards might allow costs to be recovered through provision of separated plasma suitable for fractionation.
Finally, national investment in and oversight of blood systems, far from being disruptive, have led to improved availability and quality of blood for transfusion.
The Expert Committee on Se lection and Use of Essential Medi cines will hold its biennial meet ing in April 2013. An application to include whole blood and red cells on the next Model List has been submitted and posted on the WHO website (www.who.int/ selection_medicines/committees/ expert/19/en/index.html) for pub lic comment. Patient advocacy groups, professional associations, national blood services, regula tory agencies, and others should review and comment on this ap plication. Adding blood to the Model List would encourage gov ernments to invest in infrastruc ture and the governance of blood systems and increase their efforts in blooddonor recruitment and blood collection, which should lead to the provision of safe and costeffective therapy, prevent deaths and disabilities from blood shortages, and improve health globally. 
D
o patients' reports of their health care experiences re flect the quality of care? Despite the increasing role of such mea sures in research and policy, there's no consensus regarding their legitimacy in quality assess ment. Indeed, as physician and hospital compensation becomes increasingly tied to patient feed back, health care providers and academics are raising strong ob jections to the use of patient experience surveys. These views are fueled by studies indicating that patientexperience measures at best have no relation to the quality of delivered care and at worst are associated with poorer patient outcomes. Conversely, oth er studies have found that better patient experiences -even more than adherence to clinical guide lines -are associated with bet ter outcomes. Which conclusion is correct? We believe that when designed and administered appro priately, patientexperience surveys provide robust measures of qual ity, and our efforts to assess pa tient experiences should be re doubled.
Critics express three major con cerns about patientreported mea sures, particularly those assess ing "patient satisfaction." First, they argue that patient feedback is not credible because patients lack formal medical training. They believe that patientsatisfaction measures actually capture some aspect of "happiness," which is easily influenced by factors unre lated to care. Articles in the pop ular press have even suggested that employing singing, costumed greeters would raise patientexpe rience scores. However, Jha and colleagues found that overall sat isfaction with care is positively correlated with clinical adherence to treatment guidelines. 1 One ex planation for this correlation is that patients base their satisfac
